<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39414952</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective.</ArticleTitle><Pagination><StartPage>24228</StartPage><MedlinePgn>24228</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24228</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76163-w</ELocationID><Abstract><AbstractText>Vaccination has played a critical role in mitigating COVID-19. Despite the availability of licensed vaccines, there remains a pressing need for improved vaccine platforms that provide high protection, safety, and versatility, while also reducing vaccine costs. In response to these challenges, our aim is to create a self-adjuvanted vaccine against SARS-CoV-2, utilizing Virus-Like Particles (VLPs) as the foundation. To achieve this, we produced bacteriophage (Qβ) VLPs in a prokaryotic system and purified them using a rapid and cost-effective strategy involving organic solvents. This method aims to solubilize lipids and components of the cell membrane to eliminate endotoxins present in bacterial samples. For vaccine formulation, Receptor Binding Domain (RBD) antigens were conjugated using chemical crosslinkers, a process compatible with Good Manufacturing Practice (GMP) standards. Transmission Electron Microscopy (TEM) confirmed the expected folding and spatial configuration of the QβVLPs vaccine. Additionally, vaccine formulation assessment involved SDS-PAGE stained with Coomassie Brilliant Blue, Western blotting, and stereomicroscopic experiments. In vitro and in vivo evaluations of the vaccine formulation were conducted to assess its capacity to induce a protective immune response without causing side effects. Vaccine doses of 20 µg and 50 µg stimulated the production of neutralizing antibodies. In in vivo testing, the group of animals vaccinated with 50 µg of vaccine formulation provided complete protection against virus infection, maintaining stable body weight without showing signs of disease. In conclusion, the QβVLPs-RBD vaccine has proven to be effective and safe, eliminating the necessity for supplementary adjuvants and offering a financially feasible approach. Moreover, this vaccine platform demonstrates flexibility in targeting Variants of Concern (VOCs) via established conjugation protocols with VLPs.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vuitika</LastName><ForeName>Larissa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Côrtes</LastName><ForeName>Nelson</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Interunits Graduate Program in Biotechnology, University of São Paulo, the Butantan Institute and the Technological Research Institute of the State of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaquias</LastName><ForeName>Vanessa B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Program in Pathophysiology and Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Jaqueline D Q</ForeName><Initials>JDQ</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Program in Pathophysiology and Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lira</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Interunits Graduate Program in Biotechnology, University of São Paulo, the Butantan Institute and the Technological Research Institute of the State of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prates-Syed</LastName><ForeName>Wasim A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Interunits Graduate Program in Biotechnology, University of São Paulo, the Butantan Institute and the Technological Research Institute of the State of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schimke</LastName><ForeName>Lena F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Molecular Medicine, Laboratory of Medical Investigation 29., University of São Paulo School of Medicine, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luz</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Bacteriology, Butantan Institute, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durães-Carvalho</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>São Paulo School of Medicine, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Morphology and Genetics, Federal University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interunit Bioinformatics Graduate Program, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balan</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Applied Structural Biology Laboratory, Institute of Biomedical Sciences, University of São Paulo, São Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Câmara</LastName><ForeName>Niels O S</ForeName><Initials>NOS</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology Division, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabral-Marques</LastName><ForeName>Otavio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Molecular Medicine, Laboratory of Medical Investigation 29., University of São Paulo School of Medicine, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DO'R Institute for research, São Paulo, Brazil, IDOR, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krieger</LastName><ForeName>José E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Heart Institute, Clinical Hospital, Faculty of Medicine, Laboratory of Genetics and Molecular Cardiology, Clinical Hospital, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirata</LastName><ForeName>Mario H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Program in Pathophysiology and Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabral-Miranda</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. gcabral.miranda@usp.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Interunits Graduate Program in Biotechnology, University of São Paulo, the Butantan Institute and the Technological Research Institute of the State of São Paulo, São Paulo, Brazil. gcabral.miranda@usp.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Program in Pathophysiology and Toxicology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil. gcabral.miranda@usp.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil. gcabral.miranda@usp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020/09404-0 (Post-doc Scholarship)</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>AL: 2021/03102-5 (PhD Scholarship</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>NC 2021/03508-1</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>WAPS 2021/08468-8 (PhD Scholarship)</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>GC-M: 2019/14526-0, 2020/04667-3</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089582">Adjuvants, Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="Y">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000089582" MajorTopicYN="N">Adjuvants, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">VLPs platform</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39414952</ArticleId><ArticleId IdType="pmc">PMC11484777</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76163-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76163-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kumar, A. et al. SARS-CoV-2-specific virulence factors in COVID-19. J. Med. Virol. 93 (3), 1343–1350. 10.1002/jmv.26615 (2021). Epub 2020 Nov 1. PMID: 33085084.</Citation><ArticleIdList><ArticleId IdType="pubmed">33085084</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/</Citation></Reference><Reference><Citation>DeGrace, M. M. et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 605, 640–652 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345323</ArticleId><ArticleId IdType="pubmed">35361968</ArticleId></ArticleIdList></Reference><Reference><Citation>Prates-Syed, W. A. et al. VLP-Based COVID-19 vaccines: an adaptable technology against the threat of New variants. Vaccines (Basel). 9 (12), 1409. 10.3390/vaccines9121409 (2021). PMID: 34960155; PMCID: PMC8708688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708688</ArticleId><ArticleId IdType="pubmed">34960155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirico, F., da Silva, J. A. T., Tsigaris, P. &amp; Sharun, K. Safety &amp; effectiveness of COVID-19 vaccines: a narrative review. Indian J. Med. Res. 155, 91–104 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552389</ArticleId><ArticleId IdType="pubmed">35859436</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, C. B., Farzan, M., Chen, B. &amp; Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell. Biol. 23, 3–20 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Min, L. &amp; Sun, Q. Antibodies and vaccines target RBD of SARS-CoV-2. Front. Mol. Biosci. 8, 671633 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8100443</ArticleId><ArticleId IdType="pubmed">33968996</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5 (48), eabc8413. 10.1126/sciimmunol.abc8413 (2020). PMID: 32527802; PMCID: PMC7292505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollet, J., Chen, W. H. &amp; Strych, U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv. Drug Deliv Rev. 170, 71–82. 10.1016/j.addr.2021.01.001 (2021). Epub 2021 Jan 7. PMID: 33421475; PMCID: PMC7788321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7788321</ArticleId><ArticleId IdType="pubmed">33421475</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran, B. S., Arunachalam, P. &amp; O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023785</ArticleId><ArticleId IdType="pubmed">33824489</ArticleId></ArticleIdList></Reference><Reference><Citation>Schijns, V. et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol. Rev. 296 (1), 169–190. 10.1111/imr.12889 (2020). Epub 2020 Jun 28. PMID: 32594569; PMCID: PMC7497245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497245</ArticleId><ArticleId IdType="pubmed">32594569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. N., Auclair, S. &amp; Zhu, J. Virus-like nanoparticle vaccines for inducing long-lasting immunity against infectious diseases. Natl. Sci. Rev. 11 (4), nwae032. 10.1093/nsr/nwae032 (2024). PMID: 38440215; PMCID: PMC10911813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10911813</ArticleId><ArticleId IdType="pubmed">38440215</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, X. et al. Nanovaccines for advancing long-lasting immunity against Infectious diseases. ACS Nano. 17 (24), 24514–24538. 10.1021/acsnano.3c07741 (2023). Epub 2023 Dec 6. PMID: 38055649.</Citation><ArticleIdList><ArticleId IdType="pubmed">38055649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, S. M. et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 4 (3), e4667. 10.1371/journal.pone.0004667 (2009). Epub 2009 Mar 2. PMID: 19252744; PMCID: PMC2646145.).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646145</ArticleId><ArticleId IdType="pubmed">19252744</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsen, M. O. L., Zha, Cabral-Miranda, G. &amp; Bachmann, M. F. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 34, 123–132 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28887001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, R. et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front. Immunol. 14, 1123805. 10.3389/fimmu.2023.1123805 (2023). PMID: 36845125; PMCID: PMC9947793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9947793</ArticleId><ArticleId IdType="pubmed">36845125</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq, H., Batool, S., Asif, S., Ali, M. &amp; Abbasi, B. H. Virus-like particles: Revolutionary platforms for developing vaccines against emerging Infectious diseases. Front. Microbiol. 12, 790121. 10.3389/fmicb.2021.790121 (2022). PMID: 35046918; PMCID: PMC8761975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761975</ArticleId><ArticleId IdType="pubmed">35046918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan, M., Saied, A. R. A. &amp; Sharma, M. Virus-like particles (VLPs)-based vaccines against COVID-19: where do we stand amid the ongoing evolution of SARS-CoV-2? Health Sci. Rev. 9, 100127. 10.1016/j.hsr.2023.100127 (2023).</Citation></Reference><Reference><Citation>Mohsen, M. O. et al. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J. Controlled Release 2017 March 251: 92–100. 10.1016/j.jconrel.2017.02.031</Citation><ArticleIdList><ArticleId IdType="pubmed">28257987</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian, C. et al. Recent progress on the versatility of Virus-Like particles. Vaccines (Basel). 8 (1), 139. 10.3390/vaccines8010139 (2020). PMID: 32244935; PMCID: PMC7157238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157238</ArticleId><ArticleId IdType="pubmed">32244935</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, F. &amp; Zhang, D. Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. Front. Immunol. 14, 1238649. 10.3389/fimmu.2023.1238649 (2023). PMID: 38022657; PMCID: PMC10652786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10652786</ArticleId><ArticleId IdType="pubmed">38022657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadj Hassine, I., Ben, M., Almalki, M. &amp; Gharbi, M. A. Virus-like particles as powerful vaccination strategy against human viruses. Rev. Med. Virol. 34 (1), e2498. 10.1002/rmv.2498 (2024). Epub 2023 Dec 20. PMID: 38116958.</Citation><ArticleIdList><ArticleId IdType="pubmed">38116958</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazalovska, M. &amp; Kouokam, J. C. Progress in the production of Virus-Like particles for vaccination against Hepatitis E Virus. Viruses. 12 (8), 826. 10.3390/v12080826 (2020). PMID: 32751441; PMCID: PMC7472025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472025</ArticleId><ArticleId IdType="pubmed">32751441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, D. et al. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nat. Commun. 11 (1), 2841. 10.1038/s41467-020-16639-1 (2020). PMID: 32503989; PMCID: PMC7275066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275066</ArticleId><ArticleId IdType="pubmed">32503989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar, M. W. et al. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines. 6 (1), 5. 10.1038/s41541-020-00267-3 (2021). PMID: 33420068; PMCID: PMC7794334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Miranda, G. et al. M. DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases ;6(4):107. doi: 10.3390/diseases6040107. (2018). PMID: 30469323; PMCID: PMC6313579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6313579</ArticleId><ArticleId IdType="pubmed">30469323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Miranda, G. et al. Microcrystalline Tyrosine (MCT®): a Depot Adjuvant in Licensed Allergy Immunotherapy offers New opportunities in Malaria. Vaccines (Basel). 5 (4), 32. 10.3390/vaccines5040032 (2017). PMID: 28953265; PMCID: PMC5748599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748599</ArticleId><ArticleId IdType="pubmed">28953265</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Miranda, G. et al. Virus-like particle (VLP) plus Microcrystalline Tyrosine (MCT) adjuvants enhance vaccine efficacy improving T and B cell immunogenicity and protection against Plasmodium berghei/vivax. Vaccines (Basel). 5 (2), 10. 10.3390/vaccines5020010 (2017). PMID: 28468322; PMCID: PMC5492007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492007</ArticleId><ArticleId IdType="pubmed">28468322</ArticleId></ArticleIdList></Reference><Reference><Citation>Roesti, E. S. et al. Vaccination against Amyloidogenic Aggregates in pancreatic islets prevents development of type 2 diabetes Mellitus. Vaccines (Basel). 8 (1), 116. 10.3390/vaccines8010116 (2020). PMID: 32131431; PMCID: PMC7157615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157615</ArticleId><ArticleId IdType="pubmed">32131431</ArticleId></ArticleIdList></Reference><Reference><Citation>Doucet, M. et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One. 12 (8), e0181844. 10.1371/journal.pone.0181844 (2017). PMID: 28797124; PMCID: PMC5552317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552317</ArticleId><ArticleId IdType="pubmed">28797124</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden, A. et al. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 neutralizing antibodies. Curr. Protoc. Immunol. 131 (1), e116. 10.1002/cpim.116 (2020). PMID: 33215858; PMCID: PMC7864545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864545</ArticleId><ArticleId IdType="pubmed">33215858</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino, M. L., Crooke, S. N., Manchester, M. &amp; Finn, M. G. Single-point mutations in Qβ Virus-like particles change binding to cells. Biomacromolecules. 22 (8), 3332–3341. 10.1021/acs.biomac.1c00443 (2021). Epub 2021 Jul 12. PMID: 34251176; PMCID: PMC9068229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9068229</ArticleId><ArticleId IdType="pubmed">34251176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungsuwan, S. et al. Structure guided design of bacteriophage Qβ mutants as Next Generation Carriers for Conjugate vaccines. ACS Chem. Biol. 17 (11), 3047–3058. 10.1021/acschembio.1c00906 (2022). Epub 2022 Feb 10. PMID: 35142488; PMCID: PMC9363528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9363528</ArticleId><ArticleId IdType="pubmed">35142488</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito, L. A. &amp; Singh, M. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci. ;100(1):34 – 7. doi: (2011). 10.1002/jps.22267. PMID: 20575063.</Citation><ArticleIdList><ArticleId IdType="pubmed">20575063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, X. et al. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094. 10.1038/s41578-021-00358-0 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273–2287. 10.1038/s41591-022-02061-1 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36357682</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586. 10.1016/j.ijpharm.2021.120586 (2021). Epub 2021 Apr 9. PMID: 33839230; PMCID: PMC8032477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032477</ArticleId><ArticleId IdType="pubmed">33839230</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, X. et al. Nanoparticle technology for mRNA: delivery strategy, clinical application and developmental landscape. Theranostics. 14 (2), 738–760. 10.7150/thno.84291 (2024). PMID: 38169577; PMCID: PMC10758055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10758055</ArticleId><ArticleId IdType="pubmed">38169577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon, E., Elia, U. &amp; Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin. Biotechnol. 73, 329–336. 10.1016/j.copbio.2021.09.016 (2022). Epub 2021 Oct 26. PMID: 34715546; PMCID: PMC8547895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547895</ArticleId><ArticleId IdType="pubmed">34715546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal. Transduct. Target. Ther. 8 (1), 149. 10.1038/s41392-023-01408-5 (2023). PMID: 37029123; PMCID: PMC10081433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10081433</ArticleId><ArticleId IdType="pubmed">37029123</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirley, J. L., de Jong, Y. P., Terhorst, C. &amp; Herzog, R. W. Immune responses to viral gene therapy vectors. Mol. Ther. 28 (3), 709–722. 10.1016/j.ymthe.2020.01.001 (2020). Epub 2020 Jan 10. PMID: 31968213; PMCID: PMC7054714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054714</ArticleId><ArticleId IdType="pubmed">31968213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, Y. K. et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl Med. 13 (580), eabd3438. 10.1126/scitranslmed.abd3438 (2021). PMID: 33568518; PMCID: PMC8409505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409505</ArticleId><ArticleId IdType="pubmed">33568518</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed, A. M. et al. Rapid assessment of SARS-CoV-2-evolved variants using virus-like particles. Science. 374 (6575), 1626–1632. 10.1126/science.abl6184 (2021). Epub 2021 Nov 4. PMID: 34735219; PMCID: PMC9005165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005165</ArticleId><ArticleId IdType="pubmed">34735219</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, B. A. &amp; Menachery, V. D. A new tool to probe SARS-CoV-2 variants. Science. 374 (6575), 1557–1558. 10.1126/science.abn3781 (2021). Epub 2021 Dec 23. PMID: 34941409.</Citation><ArticleIdList><ArticleId IdType="pubmed">34941409</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuitika, L. et al. Vaccines against emerging and neglected infectious diseases: an overview. Vaccines (Basel). 10 (9), 1385. 10.3390/vaccines10091385 (2022). PMID: 36146463; PMCID: PMC9503027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9503027</ArticleId><ArticleId IdType="pubmed">36146463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul, V. et al. Lessons learned from a global perspective of Coronavirus Disease-2019. Clin. Chest Med. 44 (2), 435–449 (2023). Epub 2022 Nov 24. PMID: 37085231; PMCID: PMC9684102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9684102</ArticleId><ArticleId IdType="pubmed">37085231</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, S. D., Fiedler, J. D. &amp; Finn, M. G. Assembly of hybrid bacteriophage Qbeta virus-like particles. Biochemistry. 48 (47), 11155–11157. 10.1021/bi901306 (2009). PMID: 19848414; PMCID: PMC2799296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799296</ArticleId><ArticleId IdType="pubmed">19848414</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, J. Y., Gorzelnik, K. V., Thongchol, J. &amp; Zhang, J. Structural Assembly of Qβ Virion and its diverse forms of virus-like particles. Viruses. 14 (2), 225. 10.3390/v14020225 (2022). PMID: 35215818; PMCID: PMC8880383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8880383</ArticleId><ArticleId IdType="pubmed">35215818</ArticleId></ArticleIdList></Reference><Reference><Citation>Frietze, K. M., Peabody, D. S. &amp; Chackerian, B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 18, 44–49. 10.1016/j.coviro.2016.03.001 (2016). Epub 2016 Mar 29. PMID: 27039982; PMCID: PMC4983494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983494</ArticleId><ArticleId IdType="pubmed">27039982</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, W. et al. Characterization of T-Dependent and T-Independent B cell responses to a virus-like particle. J. Immunol. 198 (10), 3846–3856. 10.4049/jimmunol.1601852 (2017). Epub 2017 Apr 17. PMID: 28416599.</Citation><ArticleIdList><ArticleId IdType="pubmed">28416599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambühl, P. M. et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. ;25(1):63–72. doi: (2007). 10.1097/HJH.0b013e32800ff5d6. PMID: 17143175.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143175</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer, P. et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. ;35(7):2031-40. doi: (2005). 10.1002/eji.200526285. PMID: 15971275.</Citation><ArticleIdList><ArticleId IdType="pubmed">15971275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 19 (1), 59. 10.1186/s12951-021-00806-7 (2021). PMID: 33632278; PMCID: PMC7905985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905985</ArticleId><ArticleId IdType="pubmed">33632278</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, X., Wang, X., Zhang, J., Xia, N. &amp; Zhao, Q. Escherichia coli-derived virus-like particles in vaccine development. NPJ Vaccines. 2, 3. 10.1038/s41541-017-0006-8 (2017). PMID: 29263864; PMCID: PMC5627247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627247</ArticleId><ArticleId IdType="pubmed">29263864</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361–379 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabel, K. G. et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science. 375 (6578), eabl6251. 10.1126/science.abl6251 (2022). Epub 2022 Jan 21. PMID: 34855508; PMCID: PMC9127715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127715</ArticleId><ArticleId IdType="pubmed">34855508</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit, M. J. et al. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. Lancet Microbe. 4 (3), e140–e148 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9848408</ArticleId><ArticleId IdType="pubmed">36681093</ArticleId></ArticleIdList></Reference><Reference><Citation>Fougeroux, C. et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat. Commun. 12 (1), 324 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804149</ArticleId><ArticleId IdType="pubmed">33436573</ArticleId></ArticleIdList></Reference><Reference><Citation>Limonta-Fernández, M. et al. An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen. N Biotechnol. 72, 11–21 (2022). Epub 2022 Aug 8. PMID: 35953030; PMCID: PMC9359770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359770</ArticleId><ArticleId IdType="pubmed">35953030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernández-Bernal, F. et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1–2 clinical trial (ABDALA Study). EClinicalMedicine. 46, 101383. 10.1016/j.eclinm.2022.101383 (2022). Epub 2022 Apr 9. PMID: 35434578; PMCID: PMC8994669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8994669</ArticleId><ArticleId IdType="pubmed">35434578</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21 (8), 1107–1119. 10.1016/S1473-3099(21)00127-4 (2021). Epub 2021 Mar 24. PMID: 33773111; PMCID: PMC7990482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990482</ArticleId><ArticleId IdType="pubmed">33773111</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, L. et al. ZF2001 Global Trial Group. Efficacy and Safety of the RBD-Dimer-Based COVID-19 Vaccine ZF2001 in Adults. N Engl J Med. ;386(22):2097–2111. doi: 10.1056/NEJMoa2202261. Epub 2022 May 4. PMID: 35507481; PMCID: PMC9127771. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127771</ArticleId><ArticleId IdType="pubmed">35507481</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes-Balbin, Y. et al. Verez Bencomo V. SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine induces a strong neutralizing immunity in Preclinical studies. ACS Chem. Biol. 16 (7), 1223–1233. 10.1021/acschembio.1c00272 (2021). Epub 2021 Jul 4. PMID: 34219448.</Citation><ArticleIdList><ArticleId IdType="pubmed">34219448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, W. H. et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim. Biophys. Acta Gen. Subj. 1865 (6), 129893. 10.1016/j.bbagen.2021.129893 (2021). Epub 2021 Mar 14. PMID: 33731300; PMCID: PMC7955913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955913</ArticleId><ArticleId IdType="pubmed">33731300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuluva, S. et al. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine. 83, 104217 (2022). Epub 2022 Aug 12. PMID: 35970020; PMCID: PMC9372721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372721</ArticleId><ArticleId IdType="pubmed">35970020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahboob, T. et al. Development of SARS-CoV-2 vaccine: challenges and prospects. Diseases. 11 (2), 64. 10.3390/diseases11020064 (2023). PMID: 37092446; PMCID: PMC10123684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123684</ArticleId><ArticleId IdType="pubmed">37092446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zepeda-Cervantes, J., Ramírez-Jarquín, J. O. &amp; Vaca, L. Interaction between Virus-Like particles (VLPs) and Pattern Recognition Receptors (PRRs) from dendritic cells (DCs): toward Better Engineering of VLPs. Front. Immunol. 11, 1100. 10.3389/fimmu.2020.01100 (2020). PMID: 32582186; PMCID: PMC7297083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297083</ArticleId><ArticleId IdType="pubmed">32582186</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, A. M. IgG subclass co-expression brings harmony to the quartet model of murine IgG function. Immunol. Cell. Biol. 94 (10), 949–954. 10.1038/icb.2016.65 (2016). Epub 2016 Aug 9. PMID: 27502143.</Citation><ArticleIdList><ArticleId IdType="pubmed">27502143</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes, C., Roesti, A., El-Turabi, E. S. &amp; Bachmann, A. Type of RNA packed in VLPs impacts IgG class switching-implications for an Influenza Vaccine Design. Vaccines (Basel). 7 (2), 47. 10.3390/vaccines7020047 (2019). PMID: 31167472; PMCID: PMC6630894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6630894</ArticleId><ArticleId IdType="pubmed">31167472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan, C. et al. Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Res. 4 (1), 54–58. 10.1186/ar383 (2002). Epub 2001 Oct 2. PMID: 11879537; PMCID: PMC64852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64852</ArticleId><ArticleId IdType="pubmed">11879537</ArticleId></ArticleIdList></Reference><Reference><Citation>Firacative, C. et al. Identification of T helper (th)1- and Th2-associated antigens of Cryptococcus neoformans in a murine model of pulmonary infection. Sci. Rep. 8, 2681. 10.1038/s41598-018-21039-z (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805727</ArticleId><ArticleId IdType="pubmed">29422616</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai, B. et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One. 3 (7), e2685. 10.1371/journal.pone.0002685 (2008). PMID: 18628832; PMCID: PMC2441860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441860</ArticleId><ArticleId IdType="pubmed">18628832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, S., Zhang, T., Zhang, Y., Wang, H. &amp; Deng, F. Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice. Virol Sin. ;33(3):213–226. doi: 10.1007/s12250-018-0030-5. Epub 2018 May 17. PMID: 29774519; PMCID: PMC6013542. (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013542</ArticleId><ArticleId IdType="pubmed">29774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosio, C. M. et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology. ;326(2):280-7. doi: (2004). 10.1016/j.virol.2004.05.025. PMID: 15302213.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302213</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395. Update in: Cell. 2020;: PMID: 32817941; PMCID: PMC7430571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604136</ArticleId><ArticleId IdType="pubmed">33160446</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, M. et al. A C57BL/6 Mouse model of SARS-CoV-2 infection recapitulates age- and sex-based differences in human COVID-19 disease and recovery. Res Sq [Preprint]. 2022 Nov 14:rs.3.rs-2194450. doi: (2022). 10.21203/rs.3.rs-2194450/v1. Update in: Vaccines (Basel). ;11(1):47. doi: 10.3390/vaccines11010047. PMID: 36415465; PMCID: PMC9681052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860616</ArticleId><ArticleId IdType="pubmed">36679892</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif, D. et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb. Pathog. 153, 104799. 10.1016/j.micpath.2021.104799 (2021). Epub 2021 Feb 18. PMID: 33609650; PMCID: PMC7889464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaan, A. A. et al. Role of inflammatory cytokines in COVID-19 patients: a review on Molecular mechanisms, Immune functions, Immunopathology and Immunomodulatory drugs to Counter Cytokine Storm. Vaccines (Basel). 9 (5), 436. 10.3390/vaccines9050436 (2021). PMID: 33946736; PMCID: PMC8145892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8145892</ArticleId><ArticleId IdType="pubmed">33946736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q. et al. Inflammation and antiviral Immune Response Associated with severe progression of COVID-19. Front. Immunol. 12, 631226. 10.3389/fimmu.2021.631226 (2021). PMID: 33679778; PMCID: PMC7930228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930228</ArticleId><ArticleId IdType="pubmed">33679778</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraj, S. S., Jalal, P. J. &amp; IL1β IL-6, and TNF-α cytokines cooperate to modulate a complicated medical condition among COVID-19 patients: case-control study. Ann. Med. Surg. (Lond). 85 (6), 2291–2297. 10.1097/MS9.0000000000000679 (2023). PMID: 37363608; PMCID: PMC10289607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10289607</ArticleId><ArticleId IdType="pubmed">37363608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>